https://www.nasdaq.com/press-release/alnylam-announces-promotion-of-dr.-akshay-vaishnaw-to-president-2022-01-04
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentation-at-40th-annual-j.p.-morgan-healthcare-conference-2022
https://www.nasdaq.com/press-release/alnylam-comments-on-fda-approval-of-leqvior-the-first-sirna-rnai-therapeutic-approved
https://www.nasdaq.com/press-release/alnylam-submits-cta-application-for-aln-app-an-investigational-rnai-therapeutic-for
https://www.nasdaq.com/press-release/alnylam-publishes-3rd-annual-patient-access-philosophy-report-demonstrating-steady
https://www.nasdaq.com/press-release/alnylam-initiates-phase-2-study-of-lumasiran-in-patients-with-recurrent-kidney-stone
https://www.nasdaq.com/press-release/alnylam-submits-cta-application-for-aln-xdh-an-investigational-rnai-therapeutic-for
https://www.nasdaq.com/press-release/alnylam-submits-regulatory-applications-to-the-u.s.-food-and-drug-administration-and
https://www.nasdaq.com/press-release/direxion-launches-mrna-etf-msgr-2021-12-09
https://www.nasdaq.com/press-release/alnylam-ranks-1-in-boston-globes-top-places-to-work-list-for-2021-2021-12-02
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentations-at-upcoming-investor-conferences-2021-11-23
https://www.nasdaq.com/press-release/alnylam-announces-2022-product-and-pipeline-goals-and-provides-program-updates-at-rd
https://www.nasdaq.com/press-release/alnylam-presents-new-data-for-zilebesiran-an-investigational-rnai-therapeutic-for-the
https://www.nasdaq.com/press-release/alnylam-to-webcast-virtual-rd-day-2021-11-12
https://www.nasdaq.com/press-release/alnylam-initiates-kardia-2-phase-2-study-of-investigational-zilebesiran-aln-agt-in
https://www.nasdaq.com/press-release/alnylam-presents-positive-results-from-illuminate-c-phase-3-study-of-lumasiran-in
https://www.nasdaq.com/press-release/alnylam-named-a-science-magazine-top-employer-for-third-consecutive-year-2021-11-01
https://www.nasdaq.com/press-release/alnylam-pharmaceuticals-reports-third-quarter-2021-financial-results-and-highlights
https://www.nasdaq.com/press-release/alnylam-announces-planned-ceo-leadership-transition-2021-10-28
https://www.nasdaq.com/press-release/alnylam-reports-positive-topline-18-month-results-from-helios-a-phase-3-study-of
https://www.nasdaq.com/press-release/alnylam-to-webcast-conference-call-discussing-third-quarter-2021-financial-results
https://www.nasdaq.com/press-release/alnylam-announces-launch-of-alnylam-challengers-a-signature-community-impact-program
https://www.nasdaq.com/press-release/alnylam-continues-scientific-leadership-in-advancement-of-rnai-therapeutics-at-the
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentation-at-chardan-virtual-5th-annual-genetic-medicines
https://www.nasdaq.com/press-release/alnylam-submits-marketing-authorization-application-to-the-european-medicines-agency
https://www.nasdaq.com/press-release/alnylam-presents-additional-9-month-data-from-helios-a-phase-3-study-of-vutrisiran-at
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentations-at-upcoming-september-investor-conferences-2021-09
https://www.nasdaq.com/press-release/alnylam-completes-enrollment-in-helios-b-phase-3-study-of-investigational-vutrisiran
https://www.nasdaq.com/press-release/alnylam-pharmaceuticals-reports-second-quarter-2021-financial-results-and-highlights
https://www.nasdaq.com/press-release/alnylam-and-peptidream-enter-into-collaboration-agreement-to-discover-and-develop
https://www.nasdaq.com/press-release/alnylam-reports-positive-topline-results-from-illuminate-c-phase-3-study-of-lumasiran
https://www.nasdaq.com/press-release/alnylam-to-webcast-conference-call-discussing-second-quarter-2021-financial-results
https://www.nasdaq.com/press-release/alnylam-initiates-kardia-1-phase-2-study-of-zilebesiran-aln-agt-in-patients-with-mild
https://www.nasdaq.com/press-release/alnylam-announces-u.s.-food-and-drug-administration-acceptance-of-new-drug
https://www.nasdaq.com/press-release/alnylam-to-host-eighth-annual-rnai-roundtable-webcast-series-2021-06-23
https://www.nasdaq.com/press-release/alnylam-announces-new-data-from-attr-amyloidosis-programs-at-the-peripheral-nerve
https://www.nasdaq.com/press-release/alnylam-completes-enrollment-in-apollo-b-phase-3-study-of-patisiran-in-transthyretin
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentations-at-upcoming-june-investor-conferences-2021-05-26
https://www.nasdaq.com/press-release/alnylam-announces-new-advances-in-attr-amyloidosis-program-2021-05-11
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentations-at-upcoming-may-investor-conferences-2021-05-04
https://www.nasdaq.com/press-release/alnylam-announces-positive-early-results-on-clinical-outcome-measures-from-illuminate
https://www.nasdaq.com/press-release/alnylam-pharmaceuticals-reports-first-quarter-2021-financial-results-and-highlights
https://www.nasdaq.com/press-release/alnylam-presents-positive-results-from-helios-a-phase-3-study-of-investigational
https://www.nasdaq.com/press-release/alnylam-to-webcast-conference-call-discussing-first-quarter-2021-financial-results
https://www.nasdaq.com/press-release/alnylam-presents-positive-late-breaking-data-from-ongoing-phase-1-study-of-aln-agt-an
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentation-at-20th-annual-needham-virtual-healthcare-conference
https://www.nasdaq.com/press-release/alnylam-announces-publication-of-illuminate-a-phase-3-study-results-for-lumasiran-in
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentation-at-stifel-3rd-annual-cns-day-2021-03-29
https://www.nasdaq.com/press-release/alnylam-to-present-full-9-month-results-from-the-helios-a-phase-3-study-of-vutrisiran
https://www.nasdaq.com/press-release/alnylam-issues-inaugural-corporate-responsibility-summary-2021-03-11
https://www.nasdaq.com/press-release/soleo-health-to-administer-alnylam-pharmaceuticals-givlaarir-givosiran-for-the
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentations-at-upcoming-march-investor-conferences-2021-02-22
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentation-at-10th-annual-svb-leerink-global-healthcare
https://www.nasdaq.com/press-release/alnylam-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-results
https://www.nasdaq.com/press-release/alnylam-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020
https://www.nasdaq.com/press-release/alnylam-launches-alnylam-p5x25-strategy-for-planned-transition-to-a-top-five-biotech
https://www.nasdaq.com/press-release/alnylam-reports-positive-topline-results-from-helios-a-phase-3-study-of-vutrisiran-in
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentation-at-39th-annual-j.p.-morgan-healthcare-conference-2021
https://www.nasdaq.com/press-release/alnylam-appoints-tolga-tanguler-chief-commercial-officer-and-also-announces-new-cemea
https://www.nasdaq.com/press-release/alnylam-announces-2021-product-and-pipeline-goals-and-provides-program-updates-at-rd
https://www.nasdaq.com/press-release/alnylam-to-webcast-virtual-rd-day-2020-12-08
https://www.nasdaq.com/press-release/alnylam-issues-2nd-annual-patient-access-philosophy-report-highlighting-broad-access
https://www.nasdaq.com/press-release/pantherx-rarer-pharmacy-chosen-as-partner-by-alnylam-pharmaceuticals-for-oxlumotm
https://www.nasdaq.com/press-release/orsini-specialty-pharmacy-expands-partnership-with-alnylamr-pharmaceuticals-as-a
https://www.nasdaq.com/press-release/alnylam-completes-enrollment-in-illuminate-c-phase-3-study-of-lumasiran-an-rnai
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentation-at-43rd-nasdaq-virtual-investor-conference-2020-11-25
https://www.nasdaq.com/press-release/alnylam-announces-innovative-value-based-agreement-framework-for-oxlumotm-lumasiran
https://www.nasdaq.com/press-release/alnylam-announces-u.s.-food-and-drug-administration-fda-approval-of-oxlumotm
https://www.nasdaq.com/press-release/alnylam-receives-approval-for-oxlumotm-lumasiran-in-the-european-union-for-the
https://www.nasdaq.com/press-release/alnylam-reports-positive-interim-results-from-ongoing-phase-1-study-of-aln-agt-an
https://www.nasdaq.com/press-release/alnylam-pharmaceuticals-reports-third-quarter-2020-financial-results-and-highlights
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentations-at-upcoming-november-investor-conferences-2020-11-02
https://www.nasdaq.com/press-release/alnylam-wins-prestigious-prix-galien-award-for-best-biotechnology-product-with-first
https://www.nasdaq.com/press-release/alnylam-named-a-top-biopharma-employer-by-science-magazine-2020-10-29
https://www.nasdaq.com/press-release/alnylam-to-webcast-conference-call-discussing-third-quarter-2020-financial-results
https://www.nasdaq.com/press-release/alnylam-presents-positive-results-from-illuminate-b-phase-3-study-in-pediatric
https://www.nasdaq.com/press-release/alnylam-receives-positive-chmp-opinion-for-oxlumotm-lumasiran-for-the-treatment-of
https://www.nasdaq.com/press-release/alnylam-reports-positive-topline-results-from-illuminate-b-phase-3-study-of-lumasiran
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentation-at-chardan-virtual-4th-annual-genetic-medicines
https://www.nasdaq.com/press-release/alnylam-highlights-prospects-for-building-an-industry-leading-attr-amyloidosis
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentations-at-upcoming-september-investor-conferences-2020-09
https://www.nasdaq.com/press-release/blackstone-and-alnylam-close-%24150-million-rd-financing-to-advance-rnai-therapeutics
https://www.nasdaq.com/press-release/alnylam-pharmaceuticals-reports-second-quarter-2020-financial-results-and-highlights
https://www.nasdaq.com/press-release/alnylam-announces-planned-transition-of-barry-greene-president-2020-08-06
https://www.nasdaq.com/press-release/alnylam-submits-cta-application-for-aln-hsd-an-investigational-rnai-therapeutic-for
https://www.nasdaq.com/press-release/alnylam-to-webcast-conference-call-discussing-second-quarter-2020-financial-results
https://www.nasdaq.com/press-release/alnylam-announces-that-the-united-kingdoms-mhra-grants-early-access-to-lumasiran-2020
https://www.nasdaq.com/press-release/alnylam-pharmaceuticals-and-taiba-group-partner-to-commercialize-rnai-therapeutics-in
https://www.nasdaq.com/press-release/alnylam-reports-new-12-month-interim-data-from-the-envision-phase-3-study-of
https://www.nasdaq.com/press-release/alnylam-to-host-seventh-annual-rnai-roundtable-webcast-series-2020-06-18
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentation-at-bank-of-america-securities-2020-napa-biopharma
https://www.nasdaq.com/press-release/alnylam-announces-publication-of-envision-phase-3-study-results-for-givosiran-in-the
https://www.nasdaq.com/press-release/alnylam-presents-positive-phase-3-results-from-illuminate-a-study-of-lumasiran-an
https://www.nasdaq.com/press-release/alnylam-announces-recipients-of-second-annual-advocacy-for-impact-grants-program-2020
https://www.nasdaq.com/press-release/alnylam-to-webcast-conference-call-discussing-full-results-from-illuminate-a-phase-3
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentations-at-upcoming-june-investor-conferences-2020-05-26
https://www.nasdaq.com/press-release/alnylam-announces-u.s.-food-and-drug-administration-has-granted-priority-review-of
https://www.nasdaq.com/press-release/alnylam-presents-new-long-term-results-from-global-open-label-extension-study-of
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentations-at-upcoming-may-investor-conferences-2020-05-11
https://www.nasdaq.com/press-release/alnylam-pharmaceuticals-reports-first-quarter-2020-financial-results-and-highlights
https://www.nasdaq.com/press-release/vir-and-alnylam-identify-rnai-therapeutic-development-candidate-vir-2703-aln-cov
https://www.nasdaq.com/press-release/alnylam-to-webcast-conference-call-discussing-first-quarter-2020-financial-results
https://www.nasdaq.com/press-release/alnylam-receives-fast-track-designation-for-vutrisiran-for-the-treatment-of-the
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentation-at-19th-annual-needham-virtual-healthcare-conference
https://www.nasdaq.com/press-release/blackstone-and-alnylam-enter-into-%242-billion-strategic-financing-collaboration-to
https://www.nasdaq.com/press-release/alnylam-completes-rolling-submission-of-new-drug-application-to-the-u.s.-food-and
https://www.nasdaq.com/press-release/alnylam-and-dicerna-form-rnai-therapeutics-collaboration-on-alpha-1-antitrypsin
https://www.nasdaq.com/press-release/vir-and-alnylam-expand-collaboration-to-advance-investigational-rnai-therapeutics
https://www.nasdaq.com/press-release/alnylam-pharmaceuticals-and-gen-sign-distribution-agreement-in-turkey-for-onpattror
https://www.nasdaq.com/press-release/vir-and-alnylam-expand-collaboration-to-advance-rnai-therapeutics-for-the-treatment
https://www.nasdaq.com/press-release/alnylam-announces-approval-of-givlaarir-givosiran-in-the-european-union-for-the
https://www.nasdaq.com/press-release/alnylam-announces-changes-to-its-board-of-directors-2020-02-27
https://www.nasdaq.com/press-release/alnylam-announces-approval-in-brazil-of-onpattror-for-the-treatment-of-hereditary
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentations-at-upcoming-march-investor-conferences-2020-02-25
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentation-at-9th-annual-svb-leerink-global-healthcare
https://www.nasdaq.com/press-release/alnylam-completes-enrollment-of-helios-a-phase-3-study-of-vutrisiran-for-the
https://www.nasdaq.com/press-release/alnylam-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results
https://www.nasdaq.com/press-release/alnylam-receives-positive-chmp-opinion-for-givlaaritm-givosiran-for-the-treatment-of
https://www.nasdaq.com/press-release/alnylam-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2019
https://www.nasdaq.com/press-release/alnylam-announces-preliminary-fourth-quarter-and-full-year-2019-global-net-product
https://www.nasdaq.com/press-release/alnylam-initiates-rolling-submission-of-new-drug-application-nda-to-u.s.-food-and
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentation-at-38th-annual-j.p.-morgan-healthcare-conference-2020
https://www.nasdaq.com/press-release/alnylam-reports-positive-topline-results-from-illuminate-a-phase-3-study-of-lumasiran
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentations-at-upcoming-december-investor-conferences-2019-11-26
https://www.nasdaq.com/press-release/alnylam-announces-2020-product-and-pipeline-goals-and-provides-updates-at-rd-day-2019
https://www.nasdaq.com/press-release/alnylam-announces-new-and-enhanced-framework-for-value-based-agreements-to-accelerate
https://www.nasdaq.com/press-release/alnylam-announces-approval-of-givlaaritm-givosiran-by-the-u.s.-food-and-drug
https://www.nasdaq.com/press-release/alnylam-announces-second-annual-advocacy-for-impact-grants-program-2019-11-19
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentation-at-stifel-2019-healthcare-conference-2019-11-12
https://www.nasdaq.com/press-release/alnylam-initiates-illuminate-c-phase-3-study-of-lumasiran-for-the-treatment-of
https://www.nasdaq.com/press-release/alnylam-pharmaceuticals-reports-third-quarter-2019-financial-results-and-highlights
https://www.nasdaq.com/press-release/alnylam-named-1-biopharma-employer-by-science-magazine-2019-10-24
https://www.nasdaq.com/press-release/alnylam-to-webcast-conference-call-discussing-third-quarter-2019-financial-results
https://www.nasdaq.com/press-release/alnylams-distinguished-chemist-mano-manoharan-receives-lifetime-achievement-award
https://www.nasdaq.com/press-release/alnylam-announces-filing-for-marketing-authorization-of-onpattror-patisiran-in-brazil
https://www.nasdaq.com/press-release/alnylam-to-webcast-presentation-at-2019-cantor-global-healthcare-conference-2019-09
https://www.nasdaq.com/press-release/alnylam-pharmaceuticals-announces-initiation-of-apollo-b-phase-3-study-of-patisiran
https://www.nasdaq.com/press-release/1000-alnylam-employees-across-the-globe-volunteer-at-5th-annual-community-service-day
https://www.nasdaq.com/press-release/alnylam-presents-new-clinical-results-for-givosiran-at-the-2019-international
https://www.nasdaq.com/press-release/alnylam-initiates-illuminate-b-phase-3-pediatric-study-lumasiran-treatment-primary
https://www.nasdaq.com/press-release/alnylam-presents-positive-complete-results-envision-phase-3-study-givosiran
https://www.nasdaq.com/press-release/alnylam-and-regeneron-announce-broad-collaboration-discover-develop-and-commercialize
https://www.nasdaq.com/press-release/regeneron-and-alnylam-announce-broad-collaboration-discover-develop-and-commercialize
https://www.nasdaq.com/press-release/detailed-research-economic-perspectives-dxc-technology-amc-networks-suncoke-energy
